{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T19:21:31Z","timestamp":1740165691493,"version":"3.37.3"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T00:00:00Z","timestamp":1703116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T00:00:00Z","timestamp":1703116800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Canc Conf J"],"DOI":"10.1007\/s13691-023-00642-6","type":"journal-article","created":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T04:49:30Z","timestamp":1703134170000},"page":"98-102","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Significant reduction in burden of metastatic disease by intermittent docetaxel therapy in a patient with castration-resistant prostate cancer"],"prefix":"10.1007","volume":"13","author":[{"given":"Takahiro","family":"Kirisawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eijiro","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoya","family":"Okuno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroki","family":"Hagimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayumu","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuo","family":"Shinoda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Motokiyo","family":"Komiyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2953-7085","authenticated-orcid":false,"given":"Yoshiyuki","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,12,21]]},"reference":[{"key":"642_CR1","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1056\/NEJMoa040720","volume":"351","author":"IF Tannock","year":"2004","unstructured":"Tannock IF, de Wit R, Berry WR et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502\u20131512","journal-title":"N Engl J Med"},{"key":"642_CR2","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1056\/NEJMoa1209096","volume":"368","author":"CJ Ryan","year":"2013","unstructured":"Ryan CJ, Smith MR, de Bono JS et al (2013) Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 368:138\u2013148","journal-title":"N Engl J Med"},{"key":"642_CR3","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1056\/NEJMoa1405095","volume":"371","author":"TM Beer","year":"2014","unstructured":"Beer TM, Armstrong AJ, Rathkopf DE et al (2014) Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 371:424\u2013433","journal-title":"N Engl J Med"},{"key":"642_CR4","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1111\/j.1464-410X.2010.09498.x","volume":"107","author":"G Di Lorenzo","year":"2011","unstructured":"Di Lorenzo G, Buonerba C, Faiella A et al (2011) Phase II study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer. BJU Int 107:234\u2013239","journal-title":"BJU Int"},{"key":"642_CR5","doi-asserted-by":"publisher","first-page":"E635","DOI":"10.1111\/j.1464-410X.2012.11364.x","volume":"110","author":"MM Heck","year":"2012","unstructured":"Heck MM, Thalgott M, Retz M et al (2012) Rational indication for docetaxel rechallenge in metastatic castration-resistant prostate cancer. BJU Int 110:E635-640","journal-title":"BJU Int"},{"key":"642_CR6","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.urology.2011.11.043","volume":"79","author":"O Caffo","year":"2012","unstructured":"Caffo O, Pappagallo G, Brugnara S et al (2012) Multiple rechallenges for castration-resistant prostate cancer patients responding to first-line docetaxel: assessment of clinical outcomes and predictive factors. Urology 79:644\u2013649","journal-title":"Urology"},{"key":"642_CR7","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1111\/bju.14239","volume":"122","author":"H Cash","year":"2018","unstructured":"Cash H, Steiner U, Heidenreich A et al (2018) Intermittent vs continuous docetaxel therapy in patients with metastatic castration-resistant prostate cancer - a phase III study (PRINCE). BJU Int 122:774\u2013782","journal-title":"BJU Int"},{"key":"642_CR8","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1111\/j.1464-410X.2010.09296.x","volume":"106","author":"JC Eymard","year":"2010","unstructured":"Eymard JC, Oudard S, Gravis G et al (2010) Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: a retrospective multicentre study. BJU Int 106:974\u2013978","journal-title":"BJU Int"},{"key":"642_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2021.100761","volume":"56","author":"SAJ Buck","year":"2021","unstructured":"Buck SAJ, Koolen SLW, Mathijssen RHJ et al (2021) Cross-resistance and drug sequence in prostate cancer. Drug Resist Updat 56:100761","journal-title":"Drug Resist Updat"},{"key":"642_CR10","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.1093\/annonc\/mds119","volume":"23","author":"J Mezynski","year":"2012","unstructured":"Mezynski J, Pezaro C, Bianchini D et al (2012) Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance? Ann Oncol 23:2943\u20132947","journal-title":"Ann Oncol"},{"key":"642_CR11","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1200\/JCO.2003.06.100","volume":"21","author":"S Halabi","year":"2003","unstructured":"Halabi S, Small EJ, Kantoff PW et al (2003) Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol 21:1232\u20131237","journal-title":"J Clin Oncol"},{"key":"642_CR12","doi-asserted-by":"publisher","first-page":"303","DOI":"10.3892\/mco.2014.469","volume":"3","author":"H Kume","year":"2015","unstructured":"Kume H, Kawai T, Nagata M et al (2015) Intermittent docetaxel chemotherapy is feasible for castration-resistant prostate cancer. Mol Clin Oncol 3:303\u2013307","journal-title":"Mol Clin Oncol"},{"key":"642_CR13","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1038\/onc.2013.235","volume":"33","author":"X Yuan","year":"2014","unstructured":"Yuan X, Cai C, Chen S et al (2014) Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis. Oncogene 33:2815\u20132825","journal-title":"Oncogene"},{"key":"642_CR14","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.eururo.2021.09.030","volume":"81","author":"RP Graf","year":"2022","unstructured":"Graf RP, Fisher V, Mateo J et al (2022) Predictive genomic biomarkers of hormonal therapy versus chemotherapy benefit in metastatic castration-resistant prostate cancer. Eur Urol 81:37\u201347","journal-title":"Eur Urol"},{"key":"642_CR15","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1002\/pros.22872","volume":"74","author":"AA Azad","year":"2014","unstructured":"Azad AA, Leibowitz-Amit R, Eigl BJ et al (2014) A retrospective, Canadian multi-center study examining the impact of prior response to abiraterone acetate on efficacy of docetaxel in metastatic castration-resistant prostate cancer. Prostate 74:1544\u20131550","journal-title":"Prostate"}],"container-title":["International Cancer Conference Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13691-023-00642-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13691-023-00642-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13691-023-00642-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,21]],"date-time":"2024-03-21T05:21:09Z","timestamp":1710998469000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13691-023-00642-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,21]]},"references-count":15,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,4]]}},"alternative-id":["642"],"URL":"https:\/\/doi.org\/10.1007\/s13691-023-00642-6","relation":{},"ISSN":["2192-3183"],"issn-type":[{"type":"electronic","value":"2192-3183"}],"subject":[],"published":{"date-parts":[[2023,12,21]]},"assertion":[{"value":"7 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"This article does not contain any studies with animals performed by any of the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}